ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
Shareholders on May 10, 2017 in New Haven, Connecticut. The results
of the matters voted on by the shareholders are set forth below.
|
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker
Non-Votes
|
|
|
|
|
|
|
|
|
|
|
Felix Baker
|
196,267,971
|
|
619,661
|
|
272,464
|
|
7,263,638
|
|
David R. Brennan
|
195,482,894
|
|
1,405,436
|
|
271,766
|
|
7,263,638
|
|
M. Michele Burns
|
172,282,654
|
|
24,605,678
|
|
271,764
|
|
7,263,638
|
|
Christopher J. Coughlin
|
196,037,779
|
|
849,761
|
|
272,556
|
|
7,263,638
|
|
Ludwig Hantson
|
196,100,754
|
|
362,478
|
|
696,864
|
|
7,263,638
|
|
John T. Mollen
|
194,479,863
|
|
2,403,223
|
|
227,010
|
|
7,263,638
|
|
R. Douglas Norby
|
193,798,065
|
|
3,077,770
|
|
284,261
|
|
7,263.638
|
|
Alvin S. Parven
|
193,387,520
|
|
3,488,246
|
|
284,330
|
|
7,263,638
|
|
Andreas Rummelt
|
196,281,132
|
|
606,646
|
|
272,318
|
|
7,263,638
|
|
Ann M. Veneman
|
195,965,172
|
|
923,105
|
|
271,819
|
|
7,263,638
|
|
2.
|
Approval of the Alexion Pharmaceuticals, Inc. 2017 Incentive
Plan: |
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
189,851,865
|
|
7,140,844
|
|
167,387
|
|
7,236,638
|
|
3.
|
Ratification of the appointment of PricewaterhouseCoopers LLP
as Alexion’s independent registered public accounting firm: |
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
202,869,029
|
|
1,266,458
|
|
288,247
|
|
4.
|
The non-binding advisory vote to approve the compensation
paid to Alexions named executive officers as described in Alexions 2017 proxy statement: |
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
190,818,160
|
|
5,556,203
|
|
785,733
|
|
7,263,638
|
|
5.
|
The non-binding advisory vote to recommend the frequency of
the non-binding advisory vote to approve the compensation paid to Alexions named executive officers. Based on the Boards recommendation and the results of the vote, the Board has determined to hold the advisory vote every year. |
|
1 year
|
|
2 years
|
|
3 years
|
|
Abstentions
|
|
178,218,411
|
|
483,598
|
|
18,161,322
|
|
296,765
|
|
6.
|
Shareholder proposal to implement confidential shareholder
voting on executive pay matters: |
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
9,844,366
|
|
185,756,642
|
|
1,559,088
|
|
7,263,638
|
Inc. appointed David Brennan Chairman of the Board of Directors. As
previously announced, Leonard Bell retired from the Board,
effective as of the 2017 Annual Meeting of Shareholders held on May
10, 2017.
About ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders. ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Recent Trading Information
ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) closed its last trading session up +1.04 at 120.08 with 3,007,170 shares trading hands.